Onglyza Heart Failure Claims
According to recent studies, Type 2 diabetes patients who take Onglyza may be at an elevated risk for heart failure. These risks are based upon a 2013 New England Journal of Medicine (NEJM) study which found a 27% increase in rate of patient hospitalization for heart failure issues.
In April 2015, the Food and Drug Administration (FDA) convened a meeting of its Endocrinologic and Metabolic Drugs Advisory Committee to assess the heart failure risk of Onglyza. The panel voted for an updated Onglyza label that warns about the in=creased risk of heart failures.
If you or a loved one has suffered heart failure and/or death, you may have a case for compensation against the manufacturer of Ongylza, Astra Zeneca.
The experienced lawyers at Davant & Associates will seek as much financial relief as possible for injured/damaged patients, and families of victims of heart failure while taking Ongyza. We will have your case reviewed as quickly as possible, and let you know whether we believe you have a case we are willing to pursue, usually within days of obtaining relevant medical records. Please contact Davant & Associates for a no obligation free case evaluation.